市場調查報告書
商品編碼
1008111

葛瑞夫茲氏病的全球市場(2020-2026)

Graves Disease Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

葛瑞夫茲氏病的全球市場:按診斷(超聲檢查、成像、放射性碘攝入量、血液樣本)、按治療(抗甲狀腺、放射性碘治療、手術),按地區、市場規模預測、共享和趨勢分析報告

在預測期內,全球葛瑞夫茲氏病市場的複合年增長率為 4.2%。甲狀腺疾病等自身免疫性疾病的日益流行創造了對其治療的需求,並推動了葛瑞夫茲氏病市場的發展。用於有效治療葛瑞夫茲氏病的治療技術的進步是市場增長的主要驅動力之一。此外,有利的報銷政策的存在,尤其是新療法開發的資金,估計也將推動市場增長。報銷政策和做法反映了對擴大醫療保健設施、診斷服務和研發活動的重大影響。贖回政策以更好的決策和戰略管理研發公司的工作,而無需擔心預算問題。醫藥研發與扶持政策密不可分。更好的報銷政策導致在醫療保健方面的大量支出,尤其是在研發方面。許多政府和私營保險公司為葛瑞夫茲氏病的診斷和治療提供的報銷進一步擴大了格雷夫斯病市場的增長。

人口對久坐生活方式的較高傾向是導致甲狀腺相關疾病的重要原因,包括甲狀腺功能亢進症、甲狀腺功能減退症、自身免疫性疾病和甲狀腺腫。由於久坐不動的生活方式,新興新興國家吸煙、飲酒和不健康飲食活動的增加趨勢不可避免地導致嚴重的自身免疫性疾病。新技術的發展使超聲波在世界各地的軟組織診斷中得到廣泛採用,預計將為預測期內的市場增長提供有利機會。然而,治療葛瑞夫茲氏病的高成本和發展中國家缺乏熟練的醫療專業人員是阻礙市場增長的某些因素。

分部展望

市場根據診斷和治療進行劃分。根據診斷,市場分為超音波、成像、放射性碘攝入和血液樣本。由於超聲技術的不斷進步以及在全球範圍內提供超音波的菲利普斯、東芝、GE Healthcare 和雅培等大公司的重大貢獻,超聲診斷在預測期內處於最高的複合年增長率。根據治療,市場分為抗甲狀腺藥物、放射性碘治療和手術治療。

2020年抗甲狀腺藥物佔據主要市場份額

從治療來看,2020年抗甲狀腺藥物細分市場佔有較大的市場份額。這是因為它是葛瑞夫茲氏病最常見的治療方法。抗甲狀腺藥物包括丙硫氧嘧啶(PTU)和甲巰咪唑(他巴唑)。這些藥物可防止甲狀腺產生過多的激素。 PTU 提供的好處之一是出生缺陷的風險低。因此,它是孕婦首選的首選治療方法。 PTU 藥物用於不能耐受 MMI、放射性碘治療或手術的人。抗甲狀腺藥物通過阻斷單碘酪氨酸和二碘酪氨酸之間產生T3和T4的偶聯反應來阻止甲狀腺激素的合成。

區域展望

全球葛瑞夫茲氏病市場是根據對市場增長有顯著貢獻的地理區域進行分析的。根據地區,市場分為北美、歐洲、亞太地區和世界其他地區。北美在格雷夫斯病市場佔有主要市場份額。甲狀腺疾病的高患病率、對甲狀腺治療和診斷的重要認識以及通過先進的醫療保健基礎設施提供的各種治療選擇是促成該地區市場高份額的關鍵因素。此外,在歐洲,生活方式的改變和 1 型糖尿病患病率的增加是影響該地區增長的幾個因素。預計亞太地區在預測期內將經歷顯著增長。

亞太地區將在全球葛瑞夫茲氏病市場實現顯著增長

在亞太地區,葛瑞夫茲氏病市場預計將顯著增長。自身免疫性疾病患病率的增加和公眾對葛瑞夫茲氏病治療意識的提高是推動區域市場增長的關鍵因素。此外,治療技術的發展、醫療基礎設施的改善和公共衛生計劃的增加是推動亞太地區市場增長的其他幾個因素。此外,該地區糖尿病患病率的上升,尤其是在中國,是推動該地區市場增長的其他主要因素之一。由於亞太地區中低收入人群人口基數大,人們普遍採用抗甲狀腺藥物等具有成本效益的治療方案。此外,該地區新興經濟體不斷上漲的醫療保健成本預計將為該地區一些發展中國家(如印度尼西亞)的醫療基礎設施薄弱提供醫療解決方案。

市場參與者展望

葛瑞夫茲氏病市場的主要參與者包括 Rodos Biotarget GmbH、Sanofi Genzyme、Macleods Pharmaceuticals Ltd.、Apitope International NV、RLC Labs Inc. Takeda Pharmaceutical Co., Ltd. 和 Omeros Corp。為了在市場上保持競爭力,這些參與者採用了各種營銷策略,包括產品發佈、併購和合作夥伴關係。

近期發展

2018 年 7 月,德國聯邦製藥和醫療器械研究所在 21 個歐盟國家批准了默克公司名為 Euthyrox 的新配方。由於該活性成分包含在 Euthyrox 的新配方中,因此 Euthyrox 有望能夠更好地控制個體左旋甲狀腺素的劑量。

2018 年 4 月,Apitope Technology (Bristol) Ltd. 公佈了 ATX-GD-59 的 I 期臨床試驗的陽性結果,ATX-GD-59 是一種用於治療格雷夫斯病的候選產品。這將使公司能夠擴大葛瑞夫茲氏病治療的市場。除非您的競爭對手推出類似產品,否則此策略將通過擁有 "先發優勢" 幫助您在未來獲得可觀的市場份額。

本報告涵蓋以下項目

  • 市場價值數據分析和預測。
  • 每個細分市場的年市場收入(以 100 萬美元為單位)。
  • 主要地理區域的國家分析。
  • 在全球氯甲烷市場運營的主要公司。根據數據的可用性,報告中還提供了與新產品發佈和相關新聞相關的信息。
  • 通過確定未來強勁增長的關鍵細分市場來分析業務戰略。
  • 市場進入和市場擴張策略分析。
  • 通過確定誰在市場上的位置來製定競爭策略。

本報告調查了葛瑞夫茲氏病的全球市場,概述了市場,分析了市場增長和障礙、市場機會、趨勢和市場規模的預測,按診斷/治療/地區、競爭形勢和主要因素。它提供系統信息,例如公司簡介。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 重要的戰略分析

第 4 章市場決定因素

  • 動機
  • 抑制要因
  • 市場機會

第 5 章市場細分

  • 按診斷
    • 超音波
    • 圖像檢查
    • 放射性碘攝入量
    • 血樣
  • 按治療
    • 抗甲狀腺藥物
    • 放射性碘治療
    • 手術

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域

第 7 章公司簡介

  • AbbVie Inc.
  • Abbott Laboratories
  • Acella Pharmaceuticals, LLC
  • Allergan PLC
  • ApitopeInternational N.V.
  • AstraZeneca PLC
  • Bayer AG
  • Biomerieux S.A.
  • East West Pharma
  • EpiVax, Inc.
  • F.Hoffman-La-Roche AG
  • GlaxoSmithKline plc.
  • Lupin, Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • RLC Labs
  • Sanofi S.A.
  • Takeda Pharmaceutical Co.Ltd.
  • Torrent Pharmaceuticals, Ltd.
目錄
Product Code: OMR2023404

Global Graves' Disease Market Research by Diagnosis (Ultrasound, Imaging tests, Radioactive iodine uptake, and Blood sample), by Treatment (Antithyroid medication, Radioactive iodine therapy, and Surgery), And Forecast 2021-2027

The global graves' disease market is growing at a CAGR of 4.2% during the forecast period. The growing prevalence of auto-immune disorders such as thyroid disorder has created the demand for its treatment which in turn is driving the graves' disease market. Advancement in treatment technology for effective treatment of graves' disease is one of the prime factors to drive the market growth. Further, the existence of favorable reimbursement policies, funding in the development of novel therapies among others are also estimated to drive the growth of the market. Reimbursement policies and practices reflect the considerable impact on the expansion of healthcare facilities, diagnosis services, and R&D activities. Reimbursement policies control the work of the research and development companies without any budget concerns and with better decisions and strategies. R&D of any drug and supporting policies go hand in hand. Better reimbursement policies draw significant spending on healthcare, particularly in research and development. Reimbursements offered by many governments and private insurance companies for Grave's disease diagnosis and treatment are furthermore augmenting the growth of Grave's disease market.

The higher inclination of the population towards a sedentary lifestyle is a significant cause of diseases related to the thyroid including hyperthyroidism, hypothyroidism, autoimmune diseases, goiter, and others. The growing trend of smoking, drinking alcohol, and unhealthy eating activity in emerging and developing countries due to sedentary lifestyles has to lead to severe auto-immune disorders. The development of new technologies that have allowed ultrasound to become more widely adopted for soft tissue diagnosis across the globe is anticipated to offer lucrative opportunities for market growth during the forecast period. However, the high cost of treatment of Graves disorders and the unavailability of skilled medical professionals in developing and under-developed economies are certain factors that are hindering the growth of the market.

Segmental Outlook

The market is segmented based on diagnosis and treatment. Based on the diagnosis, the market is segmented into ultrasound, imaging tests, radioactive iodine uptake, and blood sample. Ultrasound diagnosis method in Grave's diseases market is growing at the highest CAGR during the forecast period attributed to the increasing advancement in ultrasound technology and significant contribution of major players such as Phillips, Toshiba, GE Healthcare, and Abbott providing ultrasound across the globe. Based on the treatment segment, the market is segmented into anti-thyroid medication, radioactive iodine therapy, and surgery.

Global Graves' Disease Market Share Treatment, 2020 (%)

Source: OMR Global

Anti-Thyroid Medication Held Major Market Share in 2020

Based on the treatment segment, the anti-thyroid medication segment held a major market share in 2020. This is due to the fact that it is the most common treatment for Grave's disease. Antithyroid medications include Propylthiouracil (PTU) and Methimazole (Tapazole). These drugs prevent the thyroid to produce excess amounts of the hormone. One of the advantages provided by the PTU is that it possesses a lower risk of birth defects; hence, it is the treatment that is firstly preferred by pregnant women. PTU drugs are used for those who cannot tolerate MMI, radioactive iodine therapy, or surgery. With the anti-thyroid medications, the coupling reaction of monoiodotyrosine and diiodotyrosine for producing T3 and T4 is blocked, and therefore, the synthesis of thyroid hormone is prevented.

Regional Outlooks

Global graves' disease market analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America held a major market share in the graves' disease market in North America. The high prevalence of thyroid disorders, significant awareness about thyroid treatment and diagnosis, and availability of various treatment options due to advanced healthcare infrastructure are some of the key factors that are contributing to the high share of this regional market. Moreover, in Europe, the changing lifestyle and the growing prevalence of type-1 diabetes among others are some factors affecting the growth in the region. Asia-Pacific is estimated to be the remarkable growth during the forecast period 2021-2027.

Global Graves' Disease Market, by Region 2021-2027

Source: OMR Global

Asia-Pacific Will Have Considerable Growth in the Global Graves' Disease Market

Asia-Pacific region is expected to witness significant growth in the graves' disease market. The rising prevalence of the autoimmune disorder, increasing awareness among people with regards to graves' disease treatment are the key factors to drive the growth of the regional market. Further, development in treatment technologies, improving healthcare infrastructure, and increasing public health programs are some other factors to drive the growth of the market in the Asia-Pacific region. Moreover, the increasing prevalence of diabetes in the region, especially in China, is one of the other major factors augmenting the market growth in the region. Asia-Pacific comprises of large low- and middle-income population base, owing to which, the people generally adopt cost-effective treatment solutions such as anti-thyroid medications. Moreover, the rising healthcare spending in the emerging economies of the region is expected to provide the medical solution to the poor healthcare infrastructure of some underdeveloped countries in the region such as Indonesia.

Market Players Outlook

Key players of the graves' disease market include Rodos Biotarget GmbH, Sanofi Genzyme, Macleods Pharmaceuticals Ltd., Apitope International N.V., RLC Labs Inc. Takeda Pharmaceutical Co., Ltd., and Omeros Corp. To remain competitive in the market, these players adopt different marketing strategies such as product launches, mergers & acquisitions, and partnerships among others.

Recent Development

In July 2018, the German Federal Institute for Drugs and Medical Devices has given acceptance in 21 countries of the EU for a new formulation by Merck KGaA named Euthyrox (levothyroxine). Euthyrox is expected to have better control over individual levothyroxine dosage as the active ingredient is in the new formulation of Euthyrox enables patients.

In April 2018, Apitope Technology (Bristol) Ltd. announced the positive results of the phase I clinical trial of its product candidate ATX-GD-59 that is used for the treatment of Grave's disease. This would allow the company to expand its market in Grave's disease treatment. This strategy would help gain a significant market share in the future by having a 'first-mover advantage' unless a rival company launches a similar product.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global graves disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. GlobalGraves' Disease market by Diagnosis
    • 5.1.1. Ultrasound
    • 5.1.2. Imaging Tests
    • 5.1.3. Radioactive Iodine Uptake
    • 5.1.4. Blood Sample
  • 5.2. Global Graves' Disease Market by Treatment
    • 5.2.1. Anti- Thyroid Medication
    • 5.2.2. Radioactive Iodine Therapy
    • 5.2.3. Surgery

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Abbott Laboratories
  • 7.3. Acella Pharmaceuticals, LLC
  • 7.4. Allergan PLC
  • 7.5. ApitopeInternational N.V.
  • 7.6. AstraZeneca PLC
  • 7.7. Bayer AG
  • 7.8. Biomerieux S.A.
  • 7.9. East West Pharma
  • 7.10. EpiVax, Inc.
  • 7.11. F.Hoffman-La-Roche AG
  • 7.12. GlaxoSmithKline plc.
  • 7.13. Lupin, Ltd.
  • 7.14. Macleods Pharmaceuticals Ltd.
  • 7.15. Merck KGaA
  • 7.16. Mylan N.V.
  • 7.17. Novartis International AG
  • 7.18. Pfizer Inc.
  • 7.19. RLC Labs
  • 7.20. Sanofi S.A.
  • 7.21. Takeda Pharmaceutical Co.Ltd.
  • 7.22. Torrent Pharmaceuticals, Ltd.

LIST OF TABLES

  • 1. GLOBAL GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL ULTRASOUND MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL IMAGING TESTS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL RADIOACTIVE IODINE UPTAKE MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL BLOOD SAMPLE MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 7. GLOBAL ANTI- THYROID MEDICATION MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL RADIOACTIVE IODINE THERAPY MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL SURGERY MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 10. NORTH AMERICAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 11. NORTH AMERICAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 13. EUROPEAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 14. EUROPEAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 15. EUROPEAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 16. ASIA-PACIFIC GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. ASIA-PACIFIC GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 18. ASIA-PACIFIC GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 19. REST OF THE WORLD GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 20. REST OF THE WORLD GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. GLOBAL GRAVES' DISEASE MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (IN %)

2. GLOBAL GRAVES' DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027 (IN %)

3. GLOBAL ULTRASOUND MARKET SIZE, 2020-2027 ($MILLION)

4. GLOBAL IMAGING TESTS MARKET SIZE, 2020-2027 ($MILLION)

5. GLOBAL RADIOACTIVE IODINE UPTAKEMARKET SIZE, 2020-2027 ($MILLION)

6. GLOBAL BLOOD SAMPLE MARKET SIZE, 2020-2027 ($MILLION)

7. GLOBALANTI- THYROID MEDICATION MARKET SIZE, 2020-2027 ($MILLION)

8. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, 2020-2027 ($MILLION)

9. GLOBAL SURGERY MARKET SIZE, 2020-2027 ($MILLION)

10. US GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

11. CANADA GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

12. UK GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

13. FRANCE GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

14. GERMANY GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

15. ITALY GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

16. SPAIN GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

17. REST OF EUROPE GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

18. INDIA GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

19. CHINA GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

20. JAPAN GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

21. REST OF ASIA-PACIFIC GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

22. REST OF THE WORLD GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)